Anne M. Stowman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne M. Stowman has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro A. Gru
Department of Dermatology, Division of Dermatopathology Columbia University Irving Medical Center/NewYork‐Presbyterian New York New York USA
1 shared publication - Craig L. Slingluff
Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, USA
1 shared publication - Elizabeth M. Gaughan
University of Virginia Department of Hematology and Oncology, 200 Jeanette Lancaster Way, Charlottesville, VA, 22903, USA
1 shared publication - Joshua E. Reuss
Georgetown University, Washington, DC
1 shared publication - Paul Raymond Kunk
University of Virginia Medical Center 12 Charlottesville, VA
1 shared publication
Latest Publications
- Open Access
- 20 December 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (1) , 94
Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
Background We report a case of sarcoidosis in a patient with metastatic melanoma managed with combination ipilimumab/nivolumab. Sarcoid development has been linked with single agent immunotherapy but, to our knowledge, it has not been reported with combination ipilimumab/nivolumab treatment. This case raises unique management challenges for both the melanoma and the immunotherapy-related toxicity. Case presentation A 46 year old Caucasian female with M1c-metastatic melanoma was managed with ipilimumab/nivolumab combination. Patient experienced response in baseline lesions but developed new clinical and radiographic findings. Biopsy of new lesions at two different sites both demonstrated tumefactive sarcoidosis. Staining of the biopsy tissue for PD-L1 expression demonstrated strong PD-L1 staining of the histiocytes and lymphocytes within the granulomas. Monotherapy nivolumab was continued without progression of sarcoid findings or clinical deterioration. Conclusions Tissue biopsy for evaluation of new lesions on immunotherapy is an important step to help guide decision making, as non-melanoma lesions can mimic disease progression.
- 20 December 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (1) , 94
Open AccessSarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
Background We report a case of sarcoidosis in a patient with metastatic melanoma managed with combination ipilimumab/nivolumab. Sarcoid development has been linked with single agent immunotherapy but, to our knowledge, it has not been reported with combination ipilimumab/nivolumab treatment. This case raises unique management challenges for both the melanoma and the immunotherapy-related toxicity. Case presentation A 46 year old Caucasian female with M1c-metastatic melanoma was managed with ipilimumab/nivolumab combination. Patient experienced response in baseline lesions but developed new clinical and radiographic findings. Biopsy of new lesions at two different sites both demonstrated tumefactive sarcoidosis. Staining of the biopsy tissue for PD-L1 expression demonstrated strong PD-L1 staining of the histiocytes and lymphocytes within the granulomas. Monotherapy nivolumab was continued without progression of sarcoid findings or clinical deterioration. Conclusions Tissue biopsy for evaluation of new lesions on immunotherapy is an important step to help guide decision making, as non-melanoma lesions can mimic disease progression.